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Purpose: To investigate the expression of the matricellular protein SPARC (secreted acidic cysteine-rich glycoprotein)
in scarred human Tenon’s capsule and in cultured human Tenon’s fibroblasts (HTF), and to analyze the influence of
SPARC on cell proliferation and collagen matrix contraction in vitro.
Methods: Human Tenon's capsule scars obtained from surgical revisions after filtration surgery were analyzed for SPARC
expression by immunohistochemistry. In cultured HTF cells, SPARC expression was assessed by northern and western
blot analyses after incubation with transforming growth factor (TGF)-β1 and TGF-β2. Cell proliferation was determined
by  bromodeoxyuridine  (BrdU)–labeling  and  HTF  cells-mediated  collagen  matrix  contraction  by  morphometric
measurements of three-dimensional collagen lattices after treatment with SPARC and/or TGF-β1.
Results: In scarred human Tenon’s capsule specimens, an increased expression of SPARC was mainly localized to the
extracellular matrix and to blood vessel walls as compared to healthy control Tenon’s capsule. In cultured HTF cells,
treatment with TGF-β1 more than TGF-β2 induced the expression of SPARC both on the mRNA and protein level.
Incubation of HTF cells with SPARC resulted in an increase in collagen matrix contraction and cell proliferation.
Moreover, a combined incubation of SPARC and TGF-β1 stimulated HTF cell proliferation significantly over the levels
that were observed after single treatment.
Conclusions: Our data provide evidence that SPARC contributes to excessive wound healing and scar formation in human
Tenon’s capsules after filtration surgery and may thus represent a novel target for anti-fibrotic strategies.
Glaucoma is one of the leading causes of irreversible
blindness  worldwide.  The  estimated  number  of  people
bilateral  blinded  from  glaucoma  in  2010  will  be
approximately  8.4  million  and  11.2  million  in  2020  [1].
Several prospective randomized clinical trials demonstrate
that an increase in intraocular pressure (IOP) is the major risk
factor for development and progression of glaucomatous optic
neuropathy [2]. Therefore filtration surgery is considered to
be the most effective method to achieve a sufficient decrease
in IOP level when topical treatment or less invasive surgery
is ineffective.
The goal of filtration surgery is to establish an artificial
outflow for the aqueous humor (AH) via a scleral fistula into
the subconjunctival space. The major risk factor for failure of
filtrating surgery is excessive post-operative wound healing
in the conjunctiva and at the level of the sclerostomy sites such
that outflow resistance of the fistula is elevated by increased
extracellular matrix (ECM) deposition [3]. To limit the post-
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operative  scarring  response,  relatively  unspecific  anti-
proliferative agents, such as Mitomycin C or 5-fluorouracil,
are used to improve surgical outcomes [4,5]. However, severe
side effects have been observed [6]. Therefore analyses of the
scarring  processes  after  filtration  surgery  are  ongoing  to
identify potential alternatives.
The complex wound healing processes following injury
of  the  Tenon’s  capsule  include  proliferation,  migration,
synthesis of ECM components and collagen contraction by
human Tenon’s fibroblast (HTF) cells that are derived from
the subconjunctival space. The activation of HTF is mainly
mediated  by  cytokines  and  growth  factors  [3,7,8].  After
filtration surgery, the wound healing response is thought to be
influenced by the passage of AH and its containing growth
factors  through  the  surgical  wound  [9].  The  most  potent
growth factors in the AH to stimulate fibroblast activation are
transforming growth factor (TGF)-β1 and TGF-β2 [3,10].
Alongside  growth  factors  and  cytokines,  matrix
modulating matricellular proteins are involved in remodeling
processes and turnover of the ECM [11]. Increased expression
of these proteins may enhance pathological processes such as
scar  formation  and  tissue  fibrosis.  In  the  past  decade  the
matricellular protein SPARC (secreted protein acidic and rich
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177in cysteine), also known as osteonectin or BM-40 was shown
to  be  involved  in  scar  formation  and  in  tissue  fibrosis
[12-20].  In  accordance  with  these  observations  a  lack  of
SPARC in mice or rats markedly reduces pulmonary [21],
renal [22], dermal [23], or hepatic [24] fibrotic processes. But
on the other hand in SPARC deficient mice an accelerated
wound closure was observed [25]. Nevertheless in a recent
study, Seet and colleagues [26] could show that in SPARC
knockout  mice,  the  scarring  response  is  diminished  after
filtration surgery. These reports strongly suggest an important
role for SPARC in ECM remodeling during a fibrotic response
and  scar  formation.  Moreover,  SPARC  like  other
matricellular proteins also has the distinct potential to modify
the signaling of growth factors such as that of TGF-β via an
increased phosphorylation of Sma and Mad related protein
(Smad) 2 [27,28].
Therefore we investigated the expression of SPARC in
human Tenon’s capsule scars after filtration surgery and in
HTF cells after incubation with TGF-β1 and TGF-β2. We also
studied  proliferation  and  collagen  matrix  contraction  in
SPARC-treated HFT cells as markers for scar formation in
vitro. We found that SPARC is expressed in human Tenon’s
scars and is substantially induced in HTF cells after treatment
with TGF-β. Furthermore, proliferation and collagen matrix
contraction are increased in SPARC-treated HTF cells. Our
results provide evidence that SPARC may be involved in
excessive wound healing of human Tenon’s capsule after
glaucoma surgery.
METHODS
Sample collection and cell culture: Sample collection was
approved by the local ethic committee and was performed
after informed consent of patients, following the tenets of the
Declaration of Helsinki. Biopsies of healthy human Tenon’s
capsule  and  Tenon’s  capsule  scars  were  obtained  from
patients  with  retinal  detachment  or  primary  open-angle
glaucoma,  respectively,  during  pars  plana  vitrectomy  or
revision  surgery  after  trabeculectomy.  Patients  with  other
ocular or systemic disease, such as inflammatory diseases or
diabetes mellitus were excluded from the study.
Cultures of human Tenon’s fibroblast were established as
described previously [29]. Briefly, Tenon’s capsule biopsies
from five different healthy-controls were dissected, placed in
50 ml tissue-culture flasks in Dulbecco's modified Eagle's
medium  (DMEM/Ham's  F12;  Invitrogen,  Karlsruhe,
Germany)  containing  15%  (v/v)  fetal  calf  serum  and
antibiotic-antimycotic  solution  (10,000  U/ml  penicillin,
10,000 μg/ml streptomycin and 25 μg/ml amphotericin B; all
from Invitrogen), incubated at 37 °C in a humidified 95% air/
5%  CO2  atmosphere  and  fed  every  3  days.  Prior  to
experiments, HTF were starved 24 h in serum free cell culture
medium. For all assays, serum free cell culture medium and
2nd-4th passage cells were used.
Proliferation  assay:  Cell  proliferation  assays  of  human
Tenon’s  fibroblast  were  performed  by  using
bromodeoxyuridine  (BrdU)–labeling  of  dividing  cells
according to manufacturer’s instructions (Roche, Mannheim,
Germany). In brief, cells were seeded into 96-well plates at an
initial density of 2×103 cells/well and allowed to attach for 24
h. After another 24 h in serum free medium, the cells were
treated with various concentrations of human recombinant
SPARC  and/or  activated  TGF-β1  (200  pg/ml;  both  R&D
Systems,  Wiesbaden,  Germany).  After  3  days,  cells  were
fixed and incorporated BrdU was detected by enzyme-linked
immunosorbent assay (ELISA) using an ELISA plate reader
(Tecan, Crailsheim, Germany) at 450 nm.
Collagen  contraction  assay:  Three-dimensional  collagen
lattices were prepared as previously described [30]. Briefly,
type  I  collagen  from  rat  tail  (Sigma,  Dorset,  UK)  was
dissolved at 2 mg/ml in 0.1% acetic acid to create a stock
solution. The collagen matrix was quickly prepared on ice by
adding 6 ml of collagen stock solution to 3.6 ml of 0.1% acetic
acid, 1.2 ml of 10× concentrated DMEM, and 1.2 ml of sodium
bicarbonate solution (11.76 mg/ml) for a final concentration
of 1 mg/ml collagen. The pH was adjusted to 7.2–7.4 by
adding 0.1 mol/l sodium hydroxide solution. Fibroblasts were
then added to achieve a final concentration of 5×105 cells/ml
of  collagen  suspension;  500  μl  of  this  suspension  was
aliquoted  into  each  well  of  a  24-well  culture  plate.  After
incubation  for  15  min  at  37  °C  with  5%  CO2  for
polymerization, the matrix in each well was overlayed with
500 μl of serum-free medium containing 100 ng/ml SPARC.
The gels were gently mechanically released from the wall and
bottom  of  the  wells  with  a  sterile  spatula.  Medium  was
changed  every  3  days.  Collagen  lattices  were  scanned  at
various time points and lattice area was analyzed using the
Digivision  software  (Soft  Imaging  System,  Münster,
Germany).
RNA isolation, cDNA generation, and northern blot analyses:
After incubation, cells were washed two times with PBS and
harvested  from  cell  culture  dishes  in  Trizol  (Invitrogen)
according  to  the  manufacturer’s  recommendations.  The
integrity  of  the  total  RNA  was  confirmed  by  gel
electrophoresis. First-strand cDNA synthesis was prepared
from total RNA using the Superscript cDNA Synthesis Kit
(Invitrogen) according to manufacturer’s instructions.
A human SPARC cDNA fragment was amplified by PCR
using the primer pairs 5′-TGC CTG ATG AGA CAG AGG
TG-3′ and 5′-TAC AGG GTG ACC AGG ACG TT-3′, and
cDNA of human Tenon’s fibroblasts as template (product
length, 465 bp). PCR was performed in a final volume of 50 µl
by initial denaturation at 94 °C for 2 min, followed by 35
cycles of 30 s at 94 °C, 45 s of annealing at 55 °C, and 90 s of
extension at 72 °C. After the last cycle, the extension time was
10 min. PCR products were gel-purified by using the QIAEX
II  Gel  Extraction  Kit  (QIAGEN,  Hilden,  Germany)  and
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178cloned  into  pCRII-Topo  vector  (Invitrogen).  After
linearization of the vector with HindIII, antisense RNA probes
for SPARC were generated and labeled with DIG-11-UTP
using T7-polymerase (Roche, Mannheim, Germany).
For northern blot analysis, 10 µg of total RNA of human
Tenon’s  fibroblasts  was  separated  on  a  1%  agarose  gel
containing 6% formaldehyde and blotted onto a positively
charged nylon membrane (Roche). After transfer, the blot was
cross-linked using a UV Stratalinker 1800 (Stratagene, La
Jolla, CA). Prehybridization was performed for 1 h at 60 °C
using  the  Dig  EasyHyb-buffer  (Roche).  After  overnight
hybridization at 60 °C, membranes were washed for 5 min
with 2× SSC and 0.1% SDS at room temperature and 15 min
with 0.2× SSC and 0.1% SDS at 70 °C. For detection of
hybridization signals, membranes were blocked for 30 min at
room temperature in 1% blocking reagent, 0.1 M maleic acid,
and 0.15 M NaCl, pH 7.5, and incubated 30 min in anti-
digoxigenin-alkaline phosphatase diluted 1:10,000 (Roche).
After washing membranes two times for 15 min in 0.1 M
maleic  acid,  0.15  M  NaCl,  pH  7.5,  and  0.3%  Tween-20,
chemiluminescence  detection  was  performed  (CDP-Star;
Roche). The membranes were exposed using a BAS 3000
Imager  work  station  (Fujifilm,  Düsseldorf,  Germany).  To
monitor the integrity of RNA, the relative amounts of RNA
loaded on the gel and the efficiency of transfer, membranes
were stained with methylene blue. For densitometry AIDA
Biopackage software (Raytest, Straubenhardt, Germany) was
used.
Protein preparation and western blot analyses: For western
blot analyses to detect SPARC, confluent human Tenon’s
fibroblasts were starved overnight in serum free medium, and
incubated with activated TGF-β1 or activated TGF-β2 (1 ng/
ml; R&D Systems, Wiesbaden, Germany) for 3 days. The total
cellular  protein  fraction  was  dissolved  in
radioimmunoprecipitation  assay  (RIPA)  buffer  and,  after
homogenization,  insoluble  constituents  were  removed  by
centrifugation.  Protein  content  was  measured  by  bradford
colorimetric  assay  according  to  manufactures  instructions
(Thermo Scientific, Germany), and up to 25 µg of cytosolic
proteins  were  subjected  to  a  10%  SDS–PAGE.  Separated
proteins were transferred on a PVDF membrane (Roche) by
semidry blotting. After blocking with 5% low fat milk in PBS-
T, the membranes were incubated overnight with mouse-anti-
SPARC antibodies (Santa Cruz), diluted 1:1.000 in PBS-T.
After  washing  three  times  with  PBS-T,  membranes  were
incubated with HRP-conjugated goat-anti-mouse secondary
antibodies  at  a  1:10,000  dilution  in  PBS-T  (Millipore,
Schwalbach,  Germany).  Antibody  labeling  was  visualized
using the Immobilon HRP substrate (Millipore), documented
on a LAS 3000 Imager work station (Fujifilm, Düsseldorf,
Germany) and quantified by using the AIDA Biopackage
software  (Raytest,  Straubenhardt,  Germany).  As  loading
control and for quantification, a coomassie blue staining was
used.
Immunohistochemistry: For immunohistochemistry, samples
of three healthy-control and three scarred human Tenon’s
capsules were fixed in 4% PFA for 4 h. After washing with
1x  PBS  overnight,  samples  were  embedded  in  O.C.T
compound  (Sakura  Finetek,  Zoeterwoude,  Netherlands)  to
process  frozen  sections  according  to  standard  protocols.
Before overnight incubation at 4 °C with mouse monoclonal
anti-β-SPARC antibodies (1:100; Santa Cruz, Santa Cruz,
CA), samples were incubated in 3% BSA (BSA) solution for
30 min. As negative control, sections were incubated with 3%
BSA in PBS overnight. After three washes (10 min each) with
PBS, samples were treated for 1 h with Alexa 488 Fluor-
labeled  goat-anti-mouse  antibodies  (1:1,000;  Invitrogen).
After three washes, sections were incubated in a 1:10,000
propidium iodide solution (stock 0.33 mg/ml in PBS) for 15
min,  washed  three  additional  times  and  mounted  in
fluorescent mounting medium. Samples were analyzed on an
Axiovision  fluorescence  microscope  (Carl  Zeiss,  Jena,
Germany).
Statistics:  All  results  are  expressed  as  mean±SEM.
Comparisons between the mean variables of 2 groups were
made by a 2-tailed Student’s t-test. P values less than 0.05
were considered to be statistically significant.
RESULTS
SPARC expression is increased in human Tenon’s capsule
scars: To analyze if SPARC is expressed in scars of the
Tenon’s  capsule  after  filtration  surgery,
immunohistochemical  staining  using  specific  antibodies
against SPARC in healthy and scarred human Tenon’s capsule
was performed.
In the normal human Tenon’s capsule, a weak but specific
signal for SPARC was only detected around and within blood
vessel walls (Figure 1B). Similar to this observation, in the
scarred human Tenon’s capsule, SPARC was also localized
around  and  within  blood  vessel  walls,  but  the  staining
intensity was markedly increased when compared to healthy
specimens  (Figure  1C).  Additionally,  the  blood  vessels
showed a vasodilation in the scarred human Tenon’s capsule,
which is typical for scar tissues. In the normal human Tenon’s
capsule, only a weak signal for SPARC was detected within
the connective tissue, whereas in scars of the Tenon’s capsule
a specific staining was observed throughout the collagenous
stroma  (Figure  1).  In  the  extracellular  matrix  of  human
Tenon’s scars, a prominent localization of SPARC was seen
in  areas  of  a  denser  connective  tissue  (Figure  1C,  arrow
heads).
TGF-β induces the expression of SPARC in human Tenon’s
fibroblasts: After filtration surgery, increased levels of TGF-
β are a major risk factor for the formation of Tenon’s capsule
scars. Therefore we wondered if TGF-β1 and/or TGF-β2 can
induce the expression of SPARC in cultured HTF cells.
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179Untreated HTF cells showed only weak expression for
SPARC mRNA. After incubation of the cells with activated
TGF-β1 (1 ng/ml) and -β2 (1 ng/ml) for three days, a marked
increased  mRNA  expression  of  SPARC  was  observed  by
northern blot analyses when compared with untreated control
cells. In addition, the treatment of HTF cells with TGF-β1
caused an 18.9 fold induction of SPARC mRNA and was more
potent as that with TGF-β2 that mediates a 10.6 fold increase
(Figure 2A-C).
To investigate whether the increase in transcription of
SPARC mRNA also results in elevated protein level, western
blot analyses were performed. In untreated control cells, a
basal  protein  level  of  SPARC  expression  was  detected,
whereas  the  TGF-β1  (1  ng/ml)  and  TGF-β2  (1  ng/ml)
treatments lead to a higher synthesis rate in HTF cells. Similar
to northern blot analyses, we could also observe higher protein
levels after treatment of HTF cells with TGF-β1 (3.6 fold) as
that after incubation with TGF-β2 (2.1 fold), although it was
not such prominent like on the mRNA level. Again, TGF-β1
was  more  potent  than  TGF-β2  to  induce  SPARC  protein
synthesis (Figure 2D-F).
SPARC induces proliferation of HTF cells: During wound
healing fibroblast cell proliferation is commonly involved in
the process of scar formation. To investigate if SPARC can
Figure 1. SPARC expression is increased in human Tenon’s capsule scars. Immunohistochemistry for SPARC (green) in scarred human
Tenon’s capsule (C) shows a marked accumulation of SPARC around and within vessel walls (arrows) and in areas of condensed extracellular
matrix (arrow heads), whereas only weak signals are detected in extracellular matrix and vessel walls (arrows) of healthy tissue (B). A: control
immunostaining of a healthy Tenon’s capsule. red: propidium iodide staining; original magnification: 20×.
Figure 2. TGF-β induces expression of
SPARC in human Tenon’s fibroblasts in
vitro.  Representative  northern  blot
analysis (A, B) and densitometry (C) for
SPARC expression in HTF cells without
and  with  incubation  with  activated
TGF-β1 (1 ng/ml) or TGF-β2 (1 ng/ml)
for  three  days.  For  quantification,
SPARC  mRNA  levels  were  measured
densitometrically,  normalized  to  28S
methylene blue staining and expressed
as ×-fold to levels of untreated control
cells  (mean±SEM  of  3  independent
experiments; *p<0.05). Representative
western  blot  analysis  (D,  E)  and
densitometry  (F)  in  HTF  cells  for
SPARC  without  and  with  incubation
with  activated  TGF-β1  (1  ng/ml)  or
TGF-β2 (1 ng/ml) for three days. For
quantification,  SPARC  protein  levels
were  measured  densitometrically,
normalized to coomassie blue staining
and  expressed  as  ×-fold  to  levels  of
untreated control cells (mean±SEM of 3
independent experiments; *p<0.05).
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180promote  these  processes,  HTF  cells  were  incubated  with
different concentrations of SPARC and cell proliferation was
analyzed by BrdU-ELISA assays.
After an incubation of HTF cells with 1 ng/ml SPARC
for three days, only a slight increase of cell proliferation was
detected,  whereas  higher  concentrations  of  SPARC
significantly  induced  HTF  cell  proliferation  in  a  dose
dependent manner up to 1.6 fold when compared to untreated
controls (Figure 3A).
Because TGF-β1 is a very potent inducer of HTF cell
proliferation and also of SPARC expression, we analyzed
whether  SPARC-mediated  HTF  cell  proliferation  is  a
downstream effect of TGF-β1. Since SPARC can activate the
TGF-β signaling cascade [27] and HTF cells express TGF-β1
[31], only moderate concentrations of both factors were used
to avoid an overstimulation.
After an incubation of HTF cells with 200 pg/ml activated
TGF-β1 for 3 days a statistically significant increase of cell
proliferation of about 1.7 fold was observed in comparison to
untreated controls. In addition, the proliferation rate of TGF-
β1-treated cells was about 40% higher than after treatment
with  SPARC.  When  HTF  cells  were  incubated  with  a
combination of SPARC and TGF-β1, cell proliferation further
increased about 2.0 fold in comparison to untreated cells and
proliferation rate was enhanced by 30% than after treatment
with TGF-β1 only (Figure 3B).Therefore our data strongly
suggests additive effects of both growth factors.
SPARC  promotes  HTF  cell-mediated  collagen  gel
contraction: Since contraction of the extracellular matrix is a
characteristic  step  in  scar  formation,  we  investigated  if
SPARC can stimulate this effect in HTF cells on free-floating
three-dimensional collagen matrices in vitro. For this purpose
HTF  cells  were  incubated  with  100  ng/ml  SPARC  a
concentration  that  was  found  to  induce  highest  cell
proliferation. After day 1 of incubation, SPARC-treated HTF
cells as well as untreated controls showed only a slight effect
on gel contraction. After continued incubation with SPARC,
collagen matrix contraction was markedly enhanced when
compared  with  untreated  controls,  an  effect  that  was
statistically significant after 3 days as well as after 9 days of
incubation (Figure 4). In contrast, only a moderate reduction
in relative collagen lattice size was observed in untreated
control  cells  over  time.  These  data  strongly  indicate  a
substantial contractile effect of SPARC on HTF cells.
DISCUSSION
In the present study, we demonstrated that SPARC is present
in healthy human Tenon’s capsule, where it was restricted to
blood vessels, in agreement with findings in other tissues
[32].  In  scarred  human  Tenon’s  capsules  a  more  intense
SPARC  staining  was  observed  in  blood  vessel  walls  and
especially  throughout  the  connective  tissue.  The  higher
concentration  of  SPARC  within  this  tissue  could  lead  to
enhanced matricellular effect of SPARC within the Tenon’s
capsules.
These findings indicate that SPARC is highly expressed
in scarred human Tenon’s capsule and that Tenon’s capsule
fibroblasts could be the source of increased SPARC synthesis.
Activation of HTF cells by cytokines and growth factors
is considered to be the key effect during the subconjunctival
wound  healing  response  [33].  We  found  that  SPARC
expression  is  significantly  increased  in  HTF  cells  after
treatment with TGF-β1 and TGF-β2. Despite the fact that both
TGF-β  isoforms  provoke  a  higher  amount  of  SPARC  as
compared to untreated basal levels, we found that TGF-β1
lead to a higher increase of SPARC synthesis compared to
TGF-β2. In addition, TGF-β-mediated induction of SPARC
mRNA was much more pronounced than that of intracellular
SPARC proteins. This alleged discrepancy could be explained
by different half-lives of SPARC mRNA and protein, and by
the circumstance that SPARC is secreted and associated with
the extracellular matrix.
In  the  anterior  chamber  and  especially  in  the  AH  of
normal eyes, TGF-β2 is the predominant TGF-β isoform. Both
TGF-β1 and TGF-β2 isoforms are elevated in different types
of glaucoma. The concentration of latent/active TGF-β1 is
Figure 3. SPARC induces proliferation
of HTF cells. For quantification of cell
proliferation, HTF were incubated with
indicated concentrations of SPARC (A)
and/or 200 pg/ml TGF-β1 (B) in BrdU
containing  (10  µM)  serum  free  cell
culture  medium.  After  three  days,
incorporated BrdU level were measured
by ELISA technique and expressed as
relative  absorbance  to  untreated
controls (mean±SEM of 2 independent
experiments;  n≥24;  *p<0.01;
**p<0.001).
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181increased  in  the  AH  of  patients  with  pseudoexfoliation
glaucoma  (PEXG)  [34],  whereas  latent/active  TGF-β2  is
elevated  in  the  AH  of  patients  with  primary  open-angle
glaucoma (POAG). In POAG patients failure of the filtering
bleb after surgery is correlated with increased preoperative
TGF-β2  levels  in  AH  [35].  Further,  Nguyen  et  al.  [36]
demonstrated that there is a substantial risk of a breakdown of
blood-aqueous barrier after trabeculectomy, which could also
contribute  to  an  additional  increase  of  the  TGF-β
concentration  within  the  AH,  especially  of  TGF-β1,  the
dominant isoform in the blood. Since TGF-β1 and TGF-β2 are
potent  factors  contributing  to  an  activation  of  fibroblasts
throughout the body, increased amounts of TGF-β1 and TGF-
β2 in the AH could be major risk factors leading to a failure
of glaucoma filtration surgery by activating HTF cells. The
observed increase of SPARC expression within the scarring
tissue of the Tenon’s capsule could be mediated by TGF-β.
The activating capability of TGF-β1 and TGF-β2 on HTF
cell  functions  was  previously  demonstrated  by  numerous
studies. The TGF-β induced activation of HTF cells resulted
in an enhanced proliferation rate, an increased migration rate
and stronger collagen gel contraction. Our findings showed
that HTF proliferation can be also stimulated by SPARC,
although its effect was lower than that of TGF-β. However a
combined treatment with SPARC and TGF-β1 showed an
additive  effect  suggesting  that  SPARC  contributes  to  the
activation of HTF cells. Since basal and TGF-β-mediated
expression of extracellular matrix components is increased in
HTF cells of patients having PEX glaucoma or POAG [29], it
is  of  particular  interested  if  this  is  also  true  for  SPARC
expression and hereby a TGF-β independent scarring response
could be mediated.
Although  the  molecular  mechanisms  of  SPARC
signaling  are  still  unknown,  different  studies  showed  that
SPARC treatment provokes activation of latent TGF-β [27,
28]. Consistently, an enhanced phosphorylation of Smad2 was
observed  after  SPARC  treatment  [37],  showing  that  the
increase  in  active  TGF-β  also  led  to  an  enhanced  TGF-β
signaling. Therefore the additive effect of SPARC on TGF-
β-mediated cell proliferation might be also partially due to an
enhanced activation of TGF-β.
In  addition  to  increased  proliferation,  activated
fibroblasts  mediate  contraction  of  connective  tissue
constituting another critical step in scar tissue formation. An
assay to test whether a substance is contributing to this aspect
of the wound healing process is a collagen gel contraction
assay. We showed that SPARC can stimulate contraction of
collagen  gels  by  HTF  cells  and  thereby  contribute  to  the
scarring process.
SPARC is known to be a collagen-binding matricellular
protein  and  its  expression  is  found  to  be  elevated  during
wound healing processes [38] and in tissues with fibrotic
disorders  [12,20,39-43].  The  high  affinity  binding  site  of
SPARC for collagen type I, type III, and type IV is localized
Figure 4. SPARC promotes HTF cell-
mediated  collagen  gel  contraction.
Effects of 100 ng/ml SPARC on HTF-
mediated  collagen  contraction  at
different time points from 1 to 9 days.
The  area  of  collagen  lattices  was
quantified and plotted as relative size of
initial area. Shown are the means±SEM
of 2 independent experiments (*p<0.01;
**p<0.001; n≥10).
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182in the third domain of the SPARC protein and contains two
high  affinity  Ca2+-binding  EF  hands  [44].  The  interaction
between SPARC and collagen suggests that SPARC plays an
important role during ECM assembly. This assumption was
supported by the finding that the skin of SPARC−/− mice has
approximately half the amount of collagen as compared to
wild type littermates [45]. A decrease in collagen was also
apparent in the heart and in fat deposits of SPARC−/− mice
[46,47]. Therefore, an increased amount of SPARC within
Tenon capsule together with higher amounts of TGF-β, which
is known to increase matrix production in HTF cells, could
amplify the scarring process in the Tenon’s capsule following
filtration surgery. In accordance with this, in the SPARC−/−
mice, a pivotal role of SPARC in the organization of the
extracellular  matrix  in  the  surgically  induced  fistula  was
demonstrated.  In  these  mice  a  reduced  post-operative
subconjunctival scarring reaction was observed [26].
In  summary,  our  data  reveals  for  the  first  time  that
SPARC  is  highly  expressed  in  scarred  human  Tenon’s
capsules in vivo and that SPARC can directly induce and
amplify the effect of TGF-β on HTF cell proliferation and
collagen gel contraction in vitro. Together with observations
in SPARC−/− mice after filtration surgery it is tempting to
speculate that a modulation of SPARC expression could be a
feasible therapeutic approach to reduce excessive scarring and
subsequently to prevent failure of glaucoma filtration surgery.
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